We need to talk about CMV (CytoMegaloVirus). by Griffiths, P G et al.
We need 
to talk 
about 
CMV
Co-authored by: 
Professor Paul Griffiths, Professor Paul Heath
Professor Caroline Hollins Martin, Professor Mark kilby
Professor Mike Sharland, June 2015
0845 467 9590
infor@cmvaction.org.uk
cmvaction.org.uk 
@cmvactionuk
/CMVActionRegistered charity no: 1147633
executive Summary  4
Foreword 6
Case Study: lyra 7
the changing zeitgeist  
of CMV vaccines 8
Reducing CMV transmission 11
What midwives and childbearing  
women should know 13
Case Study: oscar 15
Management in pregnancy 16
What the future holds 18
Conclusion 20
ContentSI have infected 3 out of 5 people you will ever meet 
Yet most don’t even know that I am there
In most people I probably won’t have caused 
anything more than a mild sniffle
before I hide, unnoticed forever
Yet to an unborn baby I can cause serious harm 
I can cause miscarriages. I can cause stillbirths
2 or 3 babies are born every single day in the uk 
who have been affected by me
that’s nearly 1000 every year
these babies can have hearing loss, vision loss, 
cerebral palsy and epilepsy
at the moment, you cannot vaccinate against me
and in the uk nobody screens for me 
So you can’t stop me
but with greater awareness, I can be outsmarted 
the more people talk, the more they will know how  
to reduce their risk of exposure to me
the more know, the more they can identify the 
babies I have affected
but until you realise how vulnerable I really am,  
I am the stealth virus
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CMV or cytomegalovirus is a common infection 
that devastates lives.
It can infect people of all ages. Most healthy 
adults and children experience no long-term 
effects from it. but it is dangerous to unborn 
babies and is the most common infection 
transmitted from a pregnant woman to her 
baby. It affects more babies every year than 
down’s syndrome, toxoplasmosis or listeriosis. 
CMV is a neglected public 
health burden despite 
representing a very real 
public health concern. 
around 1 in 5 babies born 
with CMV will have problems 
such as hearing loss, 
cerebral palsy and physical 
impairment – placing 
considerable burdens on 
families as well as health, 
social and educational 
services.
over past decades, one by 
one, the scourges of polio, 
measles, mumps and rubella 
began to be eliminated in 
many countries. So why in 
the golden era of vaccine 
research has CMV been left 
behind? In the past it has 
been seen as too complex 
a virus. but the zeitgeist has 
now changed from ‘if we get 
a CMV vaccine’ to ‘when we 
get a CMV vaccine’.
We now know more about 
how CMV is spread. the 
main way that pregnant 
women catch CMV is from 
the urine and saliva of small 
children. there is a growing 
body of research that shows 
that providing pregnant 
women with this information 
can reduce the risk of 
acquiring CMV in pregnancy. 
We also know that pregnant 
women are highly motivated 
to follow preventative advice 
and that british women of 
childbearing age want to 
know more about CMV.
In the uS, many states are 
legislating to mandate better 
education and more rapid 
diagnostics. Public health 
and professional bodies in 
several countries already 
recommend that health 
professionals discuss CMV 
with pregnant patients. 
So how can this information 
be delivered effectively in the 
nHS? Midwives are perfectly 
placed to give pregnant 
exeCutIVe SuMMaRY
women advice about four 
simple hygiene precautions. 
However, many will have 
received minimal education 
on CMV since their initial 
training. Midwife educators 
should prioritise continuing 
professional development on 
CMV to equip midwives with 
the knowledge to make a 
vital difference.
even when infection in 
pregnancy is identified, there 
are many frustrations in 
managing it. unlike many 
other infectious diseases, 
there are few prevention and 
treatment options. there 
is an urgent need for more 
research into vaccination 
and treatment to prevent the 
devastating consequences 
of fetal infection. In the 
meantime, it is important 
that obstetricians and other 
professionals involved in 
antenatal care improve 
their understanding of 
susceptibility, infection and 
transmission. 
While research into CMV 
has traditionally lagged 
behind other viruses, our 
understanding is now 
evolving in more exciting 
directions than ever before. 
We also know more about 
the gaps in research that 
we need to fill and the uk 
is at the forefront of finding 
the answers. So as we near 
the 65th anniversary of the 
isolation of the human form 
of this virus, might science 
now be close to pensioning 
it off?
Given the far-reaching 
consequences for children, 
families and public 
services this is a goal that 
desperately needs to be 
achieved. but the good 
news is there’s plenty that 
can be done right now at 
little or no cost. GPs and 
midwives can advise women 
about reducing the risks 
of infection. obstetricians, 
sonographers, radiographers 
and neonatologists can 
be alert to the potential 
signs of CMV infection in 
a fetus or newborn so that 
more newborn babies can 
be diagnosed and treated 
within the first four weeks 
of life. Paediatricians and 
other professionals working 
with families can understand 
the guidelines for managing 
CMV so that more families 
receive the monitoring and 
support their child needs.
We realise that it will take 
time and collaborative 
working to achieve the vision 
of fewer babies being born 
with CMV and better support 
in place for those affected. 
but it can and must be 
achieved if we are to reduce 
the unacceptable burden on 
the hundreds of young lives 
blighted each year through 
congenital CMV infection.
let’s start that process now.
CMV is a 
negleCted 
publiC health 
burden
the good 
news is 
there’s 
plenty that 
Can be done 
right now
it will take 
tiMe to 
aChieVe the 
Vision of 
fewer babies 
being born 
with CMV
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CMV is a common infection that devastates lives.
CMV can infect people of all ages. Most healthy 
adults and children experience no long-term effects 
from it. but it is very dangerous to unborn babies  
and is the most common infection passed from  
a pregnant woman to her baby.
FoReWoRd
every year in the uk, CMV 
infection affects almost 1000 
babies. It places an extra 
burden on the nHS, social 
care, welfare and education 
systems, as well as the children 
and families who live with the 
consequences of the virus. 
lyra is my granddaughter and 
as an educational professional 
(I am a teacher of the deaf)  
I was shocked that so few of 
the healthcare professionals  
we met had heard of CMV. 
even fewer knew how to 
manage it. Yet CMV is not 
rare: it is more common than 
down’s syndrome and even 
infections that all pregnant 
women are warned about 
such as toxoplasmosis and 
listeriosis. 
CMV action is committed 
to raising awareness of this 
virus. our hope is that this 
report, We need to talk about 
CMV, will alert prospective 
parents, families, healthcare 
professionals and those 
running the health service  
of the threat of CMV. 
We need to talk about CMV:
•	 brings together evidence 
demonstrating that CMV is  
a serious public health issue
•	 Sets out, for the first time, 
what different professionals 
can do now to limit the 
impact of this virus
•	 outlines the research needed 
now, and in the future, 
including finding a vaccine 
for CMV
CMV action’s vision for the 
future is one where fewer 
babies in the uk are born 
with CMV and better support 
is in place for those who are 
affected. I hope this report  
will raise awareness of CMV 
and inspire readers to  
support all efforts to educate, 
vaccinate and eradicate this 
devastating virus. 
We can reduce the impact  
of CMV. and we need to  
start now.
Jan Pearman 
trustee and Secretary  
of CMV action
CMV affeCts alMost 
1000 
babies eVery year
lYRa 
lyra was born to parents who had never heard of 
CMV. the pregnancy was straightforward but it was 
evident at birth that lyra was a very sick baby; her 
parents were told she might not survive. 
the doctors treating lyra diagnosed CMV infection quickly but 
admitted they knew little about the infection and were liaising with 
specialists in london. the doctors started treatment with anti viral 
drugs the day after she was born. 
Scans and tests showed chronic liver damage, low platelets and 
extensive brain damage. lyra’s parents were told that it was unlikely 
she would ever walk or talk and would probably never even know 
they were her mum and dad. they had to come to terms with the 
knowledge that their daughter was severely mentally and physically 
disabled and medically fragile. 
blood tests showed that lyra’s mother had contracted the virus early 
on during the pregnancy but the infection and resulting damage had 
not been identified. 
lyra is now nearly 3 years old. CMV has affected her whole body. 
She has severe cerebral palsy. She can’t roll, sit or hold her head up. 
She has chronic liver disease, epilepsy that is complex and difficult 
to control, damage to her lungs, kidneys and spleen, scoliosis of the 
spine, dislocated hips, feeding difficulties and more. She can’t fight 
infection. She is blind. but she can hear and she smiles for her mum 
and dad. those smiles are priceless.
Jan Pearman
Grandparent
CaSe StudY
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CMV represents a very real 
public health concern.  
this virus damages more 
babies than many better 
known infections and every 
year one or two in every 200 
babies are born with CMV.  
this makes CMV the most 
common infection passed  
from mother to her baby.1
Sadly, around one in every 
five of these babies will have 
problems as a result of 
congenital CMV infection.2 
these include vision loss, 
cerebral palsy, epilepsy, 
physical impairment, as well 
as behavioural and learning 
difficulties. In addition, some 
13 per cent of babies born with 
CMV develop hearing loss,3 
and at a quarter of all cases, 
CMV infection is the leading 
cause of preventable hearing 
loss in childhood.
Clearly these problems can 
place considerable burdens 
on the affected child and their 
family. but they also place 
burdens on health, social 
and educational services. 
the cost to the nHS of 
hearing loss, for example, is 
significant; the hearing loss 
associated with CMV infection 
is frequently progressive, 
with the commonest severity 
being severe-profound, for 
which the lifelong cost for the 
recommended hearing implant 
is £82,000 - £108,000.4
Similarly, the provision of 
specialist health care for other 
conditions caused by CMV 
can be high. the total cost of 
care for epilepsy conditions 
is around £2billion in direct 
and indirect costs,5 and the 
annual recurrent cost of nICe 
recommended care for adHd 
around £40million.4 If we add 
to this the costs of nHS care 
for vision loss, cerebral palsy, 
developmental problems and 
the many other conditions 
caused by CMV, the total 
burden rises even further. 
of course, eradication of CMV 
will not completely remove all 
of these costs – since they 
can all be caused by other 
diseases – but they would at 
least remove an important 
preventable component of the 
overall total. Health economic 
assessments to more 
accurately determine some 
of these burdens after health 
economic assessments.
tHe CHanGInG zeItGeISt 
oF CMV VaCCIneS
In 1953 a nobel Prize was awarded for the discovery 
of cell culture techniques, and from this somewhat 
obscure and highly technical breakthrough was 
launched one of the most significant public health 
interventions in human history – the modern era 
of vaccination. over the next decades, one by one, 
the scourges of polio, measles, mumps and rubella 
began to be eliminated in many countries. So why 
in the golden era of vaccine research was CMV left 
behind? and how close are we now to finding  
an answer?
CMV: a neglected public health burden
the search for a vaccine
In terms of public health, CMV was an obvious 
early candidate for a vaccine. It damaged 
many more babies each year than did rubella 
for example, and the costs of treating the 
consequences are high. unfortunately, for various 
reasons, a suitable vaccine was not quickly 
identified, and researchers turned their attention 
to making successful vaccines against viruses like 
hepatitis a, hepatitis b, rotavirus and chickenpox. 
over the decades few researchers showed 
enthusiasm for tackling the problem of CMV. 
It was seen as too complex a virus because it 
infected each person more than once and can lie 
dormant or latent for years before reawakening to 
cause recurrent infections in some. the molecular 
biology of the virus itself showed it to be adept at 
evading the human immune system and many 
argued it would simply be “impossible” to make a 
vaccine against CMV.
nevertheless, some investigators persisted, citing 
the need for evidence before giving up on such an 
important cause of disease. and their persistence 
is showing encouraging signs of being rewarded. 
Signs of progress
the results of three studies in particular have 
been reported in recent yearsx?and, while none 
of the vaccines was good enough to yet offer 
to the general public, there are at least some 
signs now that there is the potential for making 
improvements through further development and 
additional clinical trials. Some of these are so-
called ‘Phase 1’ (very early) studies, but there is 
now at least one vaccine in ‘Phase 3’ trials – the 
type of large-scale study from which regulatory 
bodies are able to determine whether the vaccine 
should be made available to the general public. 
So it seems that some progress is being made.
So is there anything that the public can do to 
help? the good news is they can get involved with 
family members, friends and neighbours, and 
take part in randomised controlled trials. tens of 
thousands of volunteers will eventually be needed 
including toddlers, teenagers of both sexes and 
women of childbearing age. these studies take 
time but they will provide the best way of ensuring 
that a CMV vaccine is being given a fair chance 
to demonstrate its safety and efficacy. 
How long will it take before we have a vaccine to 
routinely protect against the terrible effects of 
congenital CMV, just as we now routinely protect 
against the effects of measles, mumps, rubella 
and polio? Realistically, it will need years or even 
decades, and we don’t know how many vaccine 
candidates will have to be evaluated before one 
is found that is good enough to be licensed. but 
the zeitgeist has definitely changed from when 
it was deemed “impossible” – we now talk not 
of “if we get a CMV vaccine” but “when we get a 
CMV vaccine”. the future may not be now, but it’s 
getting very much closer.
the future May not be 
now, but it’s getting 
Very MuCh Closer.
CMV represents a Very 
real publiC health 
ConCern Professor Paul Griffiths
Professor of Virology, university College london
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Public education
•	 In the uS the Centers for disease Control 
(CdC) recommends doctors tell pregnant 
women about CMV and is investing in a 
public education programme
•	 the state of utah have made CMV 
education mandatory and Hawaii’s 
legislature recently took the first step 
in passing their proposed law on 
communicating the dangers of CMV to 
pregnant women. Similar legislation is being 
considered in a number of other states 
including Connecticut, Illinois, tennessee and 
texas
•	 Professional and Public Health bodies 
across several other countries recommend 
that health professionals educate women 
about CMV. For example, the australian 
Society for Infectious diseases (aSId) 
recommends CMV counselling at prenatal 
and antenatal appointments. In France, the 
anaeS (agence nationale d’accréditation et 
d’evaluation en Santé) and CSHPF (Conseil 
supérieur d’hygiène publique de France) also 
recommend giving information to pregnant 
women about CMV infection
Antenatal screening
•	 testing of pregnant women is controversial 
and its use is not recommended in the uk 
or uS
•	 However Israel and eight european 
countries (France, belgium, Spain, Italy, 
Germany, austria, Portugal, and the 
netherlands) routinely screen the majority 
of pregnant women serologically for CMV. 
this routine serologic screening occurs 
without the recommendations or guidelines 
of any governmental agency, authority or 
professional medical society
Screening of neonates 
•	 Screening programmes for newborns have 
not yet been implemented at national level 
in the uS or europe but there is increasing 
enthusiasm for this among health care 
professionals
•	 In the uS a large CHIMeS study is 
evaluating how CMV screening could  
be implemented, and if it should
Other healthcare guidelines 
•	 In the uS the Institute of Medicine has 
ranked the development of a CMV vaccine 
as one of their highest priorities because of 
the lives it would save and the disabilities it 
would prevent. However, it may be a number 
of years before there is a Food and drug 
administration-approved CMV vaccine
•	 In the uk, health technology assessment 
bodies such as nICe and the SMC have  
no current plans to update guidelines 
involving CMV
Table 1: The Zeitgeist extends beyond vaccines: 
key international differences between UK and 
the rest of the world
key differences in practice in CMV between the uk and other countries 
Surprisingly, CMV is not that 
easily transmitted as it is spread 
only through close contact with 
bodily fluids. In fact, the main way 
pregnant women catch CMV is 
from the urine or saliva of young 
children. Younger children pose 
a greater transmission risk than 
older children: there are higher 
levels of virus found in their bodily 
fluids and they are more likely 
to spread these around, through 
drooling, mouthing toys and so  
on. and the virus can remain 
present in a child’s bodily fluids  
for many months or even years 
after they have recovered from  
the initial infection.4
CMV can be spread through 
all bodily fluids—including 
sexual contact and medical 
treatments such as blood 
or organ transplantation—
however, saliva is a particular 
risk. this is because CMV is 
present at higher levels in 
saliva than urine. also, many 
of the behaviours that increase 
exposure—such as sharing 
food and utensils, kissing on 
the mouth, and wiping the 
face—are very common practice 
among mothers and their young 
children. and these activities 
also allow for direct transfer of 
CMV to mucous membranes.5
ReduCInG CMV 
tRanSMISSIon
If you were to ask people what poses the most risk 
to a pregnant woman and her baby out of a dirty 
cat litter tray, an unpasteurised cheese or a drooling 
toddler, most would pick the litter tray or the cheese. 
and yet they would be completely wrong. 
When researchers first identified CMV in the 1950s—
the same decade as the chickenpox and measles 
viruses were discovered—it heralded a golden era of viral 
research.1 but whilst this research has led to effective 
treatments and vaccines that are now routinely used  
to combat many viral illnesses, research into CMV has 
often lagged behind. and perhaps most worryingly,  
only 14 per cent of british women know what CMV is.2
So how is a virus that three in every five people3 have 
caught at some point in their lives, actually spread?
the Main 
way 
pregnant 
woMen 
CatCh 
CMV is 
froM the 
urine or 
saliVa of 
young 
Children
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exposure through contact  
with urine mainly occurs  
during nappy changing. 
However, it is less likely to be 
transmitted this way than via 
saliva, as most women say  
they already clean their hands 
after a nappy change. 
aren’t all the people who’ve 
caught it already immune 
from it? unfortunately people 
who have already caught 
CMV do not have guaranteed 
protection. You can still catch  
a different strain or have a 
flare-up of the virus that’s 
already in your body.
So how does this knowledge  
of the rather messy 
transmission of CMV help us? 
although there is as yet no 
vaccine against CMV infection, 
there is a growing body of 
research that suggests risks 
can be reduced. 
Research studies from the 
uS, France and Italy have 
all provided evidence that 
providing pregnant women 
with counselling and clear 
information can reduce the risk 
of acquiring CMV in pregnancy 
– in some cases reducing the 
risk of acquiring CMV by up to 
85 per cent.7,8,9 despite this, 
information about avoidance 
of CMV infection is not 
routinely provided in the nHS.
In the uk, we have a long 
history of evidence that 
educational interventions can 
prevent congenital diseases. 
For example, efforts aimed 
at preventing foetal alcohol 
syndrome have reduced 
maternal alcohol consumption 
in pregnancy,10 prenatal vitamin 
and folic acid supplementation 
have lowered rates of neural 
tube defects,11 and antiviral use 
in pregnancy has been shown 
to reduce mother to child 
transmission of HIV.12
We also know that pregnant 
women are a highly motivated 
group who are more likely 
to follow CMV preventative 
measures than non-pregnant 
women,x? and that women of 
childbearing age in the uk 
want to know more about 
CMV: in a survey of over 
1,000 british women aged 
between 18 and 44x? 9 out 
of 10 (91 per cent) think that 
pregnant women should be 
given advice about CMV 
infection during pregnancy.2 
and after reading advice 
about how to prevent 
infection, three quarters 
(75%) of british women of 
childbearing age think that  
it is easy to prevent CMV.x?
CMV can be prevented.  
While we wait for vaccines 
and other interventions to 
become available, we have 
evidence that CMV education 
may be able to effectively 
prevent CMV infection in 
pregnancy. We know that 
pregnant women want this 
information and are willing  
to take appropriate measures 
to reduce their risk of 
acquiring CMV infection.  
our immediate priority 
therefore, should be finding 
ways in which this education 
can be effectively delivered  
to pregnant women on the 
nHS, at the point at which 
they most need it.
14%
only 14 per 
Cent of british 
woMen know 
what CMV is
our iMMediate 
priority 
should be to 
effeCtiVely 
eduCate 
pregnant 
woMen
Given the devastating consequences for the 
neonate from contracting congenital CMV in utero, 
it is imperative that both health care professionals 
and women receive education about reducing the 
risks of transmission.
WHat MIdWIVeS and 
CHIldbeaRInG WoMen 
SHould knoW
the risks of childbearing women contracting 
CMV raises significant responsibilities for 
health and social care professionals in terms 
of prevention and management. Humans are 
desirable hosts and bodily fluids are a keen 
source of transmission of CMV. So, what should 
health and social care professionals be doing to 
play their part in reducing the number of infants 
affected by the virus?
education
Routine provision of health 
information is a pivotal step 
in encouraging childbearing 
women to understand how 
to avoid CMV transmission. 
transmission of CMV occurs 
via bodily fluids, e.g., urine, 
saliva, vaginal secretions, 
semen, breastmilk, blood 
transfusions and organ 
transplants. Primary infection 
of childbearing women 
occurs in around 0.15-2.0% 
of all pregnancies (nigro & 
adler, 2011) and can lead to 
catastrophic consequences 
for the infant who contracts 
CMV in utero. Hence, as part 
of routine preconception and 
antenatal care, midwives must 
provide childbearing women 
with advice to reduce their 
risk of contamination by CMV. 
the simple and most effective 
education that midwives 
can offer couples planning 
or already pregnant involves 
four very simple hygiene 
precautions.
education costs little and is 
key to reducing the spread 
of CMV. education regarding 
CMV is aimed at reducing 
infant risk of developing Intra 
uterine Growth Retardation 
(IuGR), hyperbilirubinemia, 
hepatosplenomegaly, 
thrombosytopenia, and 
microcephaly, all of which 
cause serious morbidity 
problems and often death.
don’t Share,  
Wash with Care
1 avoid placing objects in your mouth that have 
previously been 
in an infant’s 
mouth e.g. avoid 
food, cup and 
utensil sharing, or 
sucking a child’s 
dummy to clean 
it after it has 
been dropped.
2  avoid kissing young children under the age of 
6 on the mouth 
or cheek. Instead, 
kiss them on 
the head or give 
them a big hug. 
3  Wash your hands thoroughly with soap and water 
after coming into 
contact with any 
bodily fluids. this 
includes after a 
nappy change, 
or after wiping a 
toddler’s nose or 
mouth.
4  thoroughly cleanse items that have been in 
contact with body 
fluids and may 
have become 
contaminated.Professor Paul Heath
Professor of Paediatric 
Infectious diseases,  
St George’s Hospital
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Midwife education
the midwife is perfectly placed 
to increase delivery of CMV 
education to both staff and 
childbearing families, yet 
many have received minimal 
education on the topic since 
their initial training. despite 
the growing body of published 
evidence that emphasises 
the importance of increasing 
health education in attempts 
to reduce CMV transmission 
(adler, 2011; bate et al., 2010; 
Cannon, 2009; Colugnati et 
al., 2007; Cordier et al., 2010; 
dollard et al., 2007; Jacobsen 
et al., 2010; nigro & adler, 
2011; von Gartzen & Hollins 
Martin Martin, 2013), in many 
countries there lacks provision 
of directives to vital health 
care professionals, such as 
general practitioners, midwives, 
neonatal paediatricians and 
nurses about this subject. this 
finding sharply contrasts with 
education designed for delivery 
in relation to other teratogenic 
infections in pregnancy, e.g. 
listeriosis and toxoplasmosis, 
which represent far less 
danger to the infant. Improving 
education that teaches people 
how to avoid contamination 
is key to reducing CMV 
spread. With this in mind, 
midwifery educators in the uk 
should consider advancing 
education for midwives as 
part of continuing professional 
development. For example, 
content of curriculum should 
include:
•	 How to prevent CMV 
infection spread (don’t 
Share, Wash with Care)
•	 Provide a clear definition  
and description of CMV 
signs and symptoms
•	 discuss prevalence of CMV 
•	 discuss brutal consequences 
for a fetus who has 
contracted congenital CMV 
CMV action and the Royal 
College of Midwives have 
developed an e-learning 
training module to promote 
and support further education 
for midwives on CMV. It is 
aimed at enhancing midwives 
understanding as well as 
increasing their confidence to 
counsel women about CMV 
and its serious consequences. 
evidence supports that high 
quality training in prevention 
and management of CMV 
markedly reduces mortality 
and morbidity of fragile infant 
lives.
to conclude, educating 
women to diminish CMV 
risk is enormously important 
if midwives are to make a 
difference. Clearly a lot is 
yet to be tackled if we are 
to eradicate CMV risk and 
spread. In essence, the 
key variable for reducing 
CMV transmission involves 
straightforward hygiene 
measures. 
Professor Caroline Hollins 
Martin
Professor in Maternal Health, 
edinburgh napier university
discussing CMV with childbearing women may make some feel 
anxious. nevertheless, given the catastrophic consequences for 
the infant of contracting congenital CMV in utero, it is imperative 
that both health care professionals and women receive carefully 
measured educational messages about its prevention (von Gartzen 
& Hollins Martin (2013). 
education could be further strengthened by widening general 
public health messages about how to prevent the spread of CMV 
infection. For example, teaching adults and older children thorough 
methods of hand hygiene and how to avoid spread between children 
in day care facilities. education programmes that extend midwives 
knowledge about CMV are clearly required, e.g. organising study 
sessions for all grades of staff and increasing the amount and level 
of CMV education in midwifery curriculum. Further training  
in prevention and management of CMV would profoundly improve 
long-term infant mortality and morbidity statistics. 
It is the responsibility of midwives to deliver information about  
CMV in a balanced way so as not to cause alarm. the spread  
of CMV can be avoided and whilst it is hard for busy women  
to avoid every potential exposure, simply improving hygiene 
measures can markedly reduce the risk of transmission.  
to this effect, CMV action has developed a range of education  
for childbearing women (cmvaction.org.uk). 
eduCation 
prograMMes 
that extend 
MidwiVes 
knowledge 
about CMV 
are Clearly 
required
after trying for a baby for two 
years, we luckily became pregnant 
with out first child just two days 
before we signed the paperwork 
to undergo IVF treatment. a lucky 
miracle I called it.
I’d spent so much time looking 
into fertility and how difficult 
getting pregnant can actually be!
I’m also a midwife of eleven years, 
with experience mostly on the 
labour ward but also in teaching 
and more recently community, so 
seeing people everyday and them 
telling me their ‘lucky’ stories of 
falling pregnant made my two 
years very long indeed.
However, we were lucky, we had  
no bleeding, no blood pressure 
issues, the down’s syndrome 
screening came back very low 
and, despite sickness that lasted 
until 22 weeks and horrendous 
heartburn, I couldn’t complain!
My midwife started measuring me 
at 26 weeks when she picked up 
that I was SFd (small for dates.) I 
also never felt my baby move.
I started undergoing serial growth 
scans. I send my own patients 
for these all the time and they 
generally come back fine, so I 
wasn’t worried. My consultant 
did a toRCH blood screen for 
infections. the toRCH screen is 
a group of blood tests that check 
for several different infections 
in a newborn. toRCH stands 
for toxoplasmosis, rubella, 
cytomegalovirus, herpes simplex, 
and HIV, but it can also include 
other newborn infections.
Well I knew I was fit and healthy 
and didn’t have any infections, but 
it’s only a blood test, so why not?
that’s when my world crumbled. 
I had contracted CMV at some 
point during the first trimester, 
meaning my baby could be 
infected, although the doctors 
reassured us out baby may not 
be ‘affected’. Whilst I’d heard of 
it, I had never known anyone who 
had had cmv. How on earth had I 
picked this up? Where had it come 
from? this was my fault. of course 
I’ve since gone on to read about 
how it is contracted and with all 
my work with families and children, 
who knows where it came from?
We started googling and found 
that he may have some learning 
disabilities or mild hearing loss, 
not a problem we thought.
the consultant suggested an 
amniocentesis, which we had 
at 33+1 weeks. We also had a 
brain scan which now showed 
ventriculomegaly, some brain 
abnormalities. We then went onto 
have an MRI scan at the John 
Radcliffe Hospital in oxford. our 
baby was disagnosed with severe 
CMV, there was poor growth, 
enlarged liver / abdomen, a small 
head and no brain activity at all. 
our beautiful baby, oscar William, 
was stillborn at 33+6 weeks, on 
9th March 2015, my shining star. 
His death is still, obviously, fresh 
and everyday is a struggle, from 
simply watching baby adverts on 
tV, to seeing friends with babies or 
looking through oscars’ photos.
I’m now on maternity leave and 
want to raise more awareness and 
support CMV action as much as 
I can.
Sharon Robinson
Midwife
CaSe StudY
oSCaR
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CMV is the largest of the 
Herpes virus family. like 
all Herpes viruses, a first or 
‘primary’ infection can occur 
at any time, but it may also 
remain ‘latent’ to be re-
activated later in life. this 
can happen for example in 
someone whose immune 
system is suppressed, or 
if they have experienced 
a stressful stimulus, in 
which case it is known as a 
‘secondary’ infection. 
estimates vary by ethnic 
group, but overall around 
three out of every five people 
in the uk have been infected 
with CMV at some point in 
their life, usually early on. this 
leaves around two in every five 
pregnant women susceptible 
to a primary infection, and 
between one and four out  
of every hundred pregnancies 
will see a mother infected  
by CMV for the first time.  
of those who become infected 
when pregnant, almost a third 
(32 per cent) will transmit  
the infection to their unborn 
baby. once infected, up to  
15 per cent of unborn babies 
will show signs of disease,  
and a similar proportion 
of babies who have no 
symptoms at all will go on  
to develop permanent 
problems, of which the most 
common is hearing loss. 
CMV infection during 
pregnancy is most often 
ManaGeMent 
In PReGnanCY
there are many frustrations in the management 
of CMV infection in pregnancy. unlike many other 
infectious diseases—such as rubella (German 
Measles), toxoplasmosis and chickenpox—there 
are few prevention and treatment options for 
CMV. Clearly there is a need for more research 
into vaccination and treatment to prevent the 
devastating consequences of this infection to the 
unborn baby. In the meantime it is important that 
obstetricians and other professionals involved in 
antenatal care improve their understanding of this 
infection, and counsel pregnant women accordingly.
suspected and diagnosed 
when an ultrasound scan 
shows suspicious features. 
these include the baby being 
small, with low amniotic fluid 
(oligohydramnios), echogenic 
(bright) kidneys and in some 
cases brain abnormality 
(usually water on the brain 
or hydrocephalus). Such 
cases are usually referred to 
a specialist fetal medicine 
centre where a detailed 
scan can be performed by 
an expert. Since testing the 
mother’s blood can produce 
inconclusive results, the 
majority of experts will want 
to perform an amniocentesis 
test to identify CMV dna, and 
also look for other signs such 
as a low platelet count in the 
baby’s blood.
In such cases, treatment 
options are limited, and 
even when treatment is 
administered it may not 
prevent damage to the baby. 
the use of antiviral medicines 
such as ganciclovir (either by 
treating the mother or directly 
into the baby by in-utero 
transfusion) may reduce the 
amount of circulating virus, 
and improve platelet count 
and liver function tests in the 
baby. However once damage 
has occurred it is unlikely to 
be reversed. Currently there is 
little high quality or definitive 
evidence on the most effective 
ways to treat CMV infection in 
pregnancy. there have been 
no randomised controlled 
trials proving that antiviral 
treatment works and reduces 
handicap rates, and more 
research studies are urgently 
needed.
Routine screening for 
CMV during pregnancy is 
not performed in the uk. 
the national Screening 
Committee has recommended 
against CMV screening 
in the antenatal period, 
because there is uncertainty 
about the risk to the baby 
when maternal infection is 
diagnosed and because the 
effectiveness of treatment 
has not been confirmed. 
However, the consequences 
of this infection in pregnancy 
can be devastating. Public 
health measures are urgently 
needed to reduce the risks 
of infection in high risk 
individuals in particular (for 
example pregnant health care 
workers, teacher, and women 
with young children), and all 
pregnant women should be 
routinely counselled about 
the need for hygiene and 
avoidance of contact with 
small children’s saliva and 
urine during pregnancy. 
In reality, however, it is hard 
to avoid every possible 
exposure, and there is 
certainly a need for more 
research into the development 
of vaccines which could 
be safe and effective in 
women of reproductive 
age. In the meantime, 
more understanding of the 
pathogenesis of susceptibility, 
infection and transmission 
to the unborn baby during 
pregnancy can only help in 
improving outcomes in this 
little-known but potentially 
devastating disease process.
32%
will transMit the 
infeCtion to their 
unborn baby. 
routine 
sCreening 
for CMV 
during 
pregnanCy 
is not 
perforMed  
in the uk
Professor Mark Kilby
Clinical Scientist and Honorary 
Consultant in Fetal Medicine, 
birmingham Women’s 
Foundation trust
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Identifying and 
treating CMV infection
Much of the research in the 
uk has focussed on diagnosis 
and treatment. Hearing loss 
at birth is one of the most 
common symptoms of CMV. 
Yet some CMV babies who fail 
their newborn hearing screen 
are not diagnosed with CMV in 
time to start antiviral treatment, 
which must happen in the first 
month of life in order to limit 
further deterioration of hearing. 
to address this issue, a series 
of studies in the uk (beSt1 
and beSt2) has explored 
the benefits and feasibility of 
integrating testing for CMV 
within the existing newborn 
hearing screening programme. 
Results from these studies 
have shown that testing for 
CMV is both acceptable to 
97 per cent of parents, and 
feasible in ‘real life’ practice.x?. 
newborn hearing screeners felt 
confident in performing the 
tests and were able to screen 
around eight out of every ten 
babies referred for further 
hearing assessment.x?
Research in this area is 
emerging in ever more 
WHat tHe FutuRe HoldS
While research into CMV infection has traditionally 
lagged somewhat behind that of other viruses, our 
understanding is now evolving in more exciting 
directions than ever before. In addition, we know 
more about the gaps in research that we need 
to fill. So as we near the 65th anniversary of the 
isolation of the human form of this virus, might 
science now be near to pensioning it off?
Recent years have seen important steps forward 
in CMV research, both in the uk and around the 
world, with studies planned or underway across the 
entire spectrum of the infection, from diagnosis and 
screening, through to transmission, treatment and 
prevention. Yet important gaps in our understanding 
still exist and the uk is very much at the forefront of 
finding the answers.
innovative directions, including 
development of an easy to 
use test to diagnose CMV that 
uses nanotechnology – a high 
tech yet low cost device that 
could enable even more babies 
to be tested and diagnosed. x?
the picture on CMV treatment 
for newborns is evolving 
rapidly. a uk/uS collaboration 
reporting in 2013 published 
evidence on the benefits 
and risks of oral antiviral 
medicines and showed that 
longer treatment could result in 
improved outcomes compared 
to shorter treatment.x? In 
addition, further research is 
now underway that will explore 
the benefits of oral antiviral 
treatment for children with 
sensorineural hearing loss and 
congenital CMV up to the age 
of 4 years.x? this could mean 
that more children have the 
option of treatment, which is 
especially important for those 
who develop hearing problems 
later on. 
Where to next?
Research has come a long 
way in recent years, yet some 
important knowledge gaps 
remain. Currently several 
early studies are looking at 
new approaches in treatment, 
such as immunoglobulins 
and antiviral medicines,x? as 
well as the ways of reducing 
transmission from an infected 
mother to her unborn child.x? 
Clearly, while some of this 
research appears promising, 
we need results from larger 
randomised studies to confirm 
initial findings.
In addition, we need to know 
more about the overall impact 
of this infection and where 
we should focus our efforts in 
combating it. the life Study 
– the largest ever uk-wide 
cohort study of babies and 
young children – will look 
at the burden of disease of 
congenital CMV and assess 
which women get infected or 
re-infected.x? We also need 
to know which babies with 
infection at birth more likely to 
have long-term disease – can 
we predict those destined for 
hearing loss?x? and do babies 
with less severe symptoms 
of disease receive the same 
benefits from treatment as 
those who do not?x?
We know that, ultimately, 
preventing CMV depends on 
developing a vaccine. there is 
a clear need for more clinical 
trials of potential vaccine 
candidates. 
So while we wait for the 
answers to these questions, our 
focus should be on two things: 
diagnosis and education. 
First, we have shown that 
babies who are at risk of 
CMV-related hearing loss can 
be tested for CMV quickly 
and easily within the nHS. 
We now need a larger-scale 
implementation study to fully 
assess the potential costs 
and savings, so that nHS 
commissioners have the 
information they need to make 
decisions about improving 
neonatal pathways.
Second, there exists 
a substantial body of 
international evidence showing 
that educating pregnant 
women about CMV can reduce 
infection in pregnancy. We 
know education works – we 
now need to explore how CMV 
education can most effectively 
be delivered within the nHS.
eduCating 
pregnant 
woMen 
about CMV 
Can reduCe 
infeCtion in 
pregnanCy
researCh 
has CoMe a 
long way in 
reCent years, 
yet soMe 
iMportant 
knowledge 
gaps reMain.
Professor Mike Sharland
Professor of Paediatric 
Infectious diseases,  
St George’s Hospital
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CMV action are 
recommending a number 
of minimum standards of 
care for pregnant women 
and babies affected by 
CMV (see overleaf). these 
minimum standards of 
care can be introduced 
as soon as today. experts 
attending an international 
CMV conference in 
brisbane in May 2015 
agreed unanimously that 
CMV counseling should 
be given to all pregnant 
women. Government and 
professional bodies in 
many countries such as the 
uS, France, australia and 
the netherlands already 
recommend that this 
happens. However advice 
on CMV prevention is not 
routinely given within the 
nHS. 
Most of the minimum 
standards of care that families 
with a baby affected by CMV 
should expect from health 
professionals can also be 
introduced immediately.
over the longer term it is also 
important to address other 
aspects of CMV:
•	 Managing infection in 
pregnancy: the uk national 
Screening Committee 
recommends against 
systematic population 
screening for CMV in 
pregnancy. However 
individual cases will still be 
identified in the course of 
routine antenatal care. each 
health community should 
therefore develop and 
implement local guidelines 
for: 
 - testing for CMV should 
there be suspicion of 
infection.
 - Management and 
monitoring when infection 
during pregnancy is 
detected.
 - diagnosing CMV in 
newborns:  Research into 
treatment and diagnostic 
technology is underway.  
as new evidence emerges 
the national Screening 
Committee should review 
its position on universal 
newborn screening.
•	 Managing CMV after 
diagnosis: Health 
professionals such as 
audiologists, paediatricians 
and neurologists, who are 
working with families, should 
ensure that monitoring 
appointments occur at 
recommended intervals. 
•	 Identifying late-onset 
problems: early years 
professionals and support 
workers must be aware of the 
particular risk CMV brings of 
late-onset and progressive 
hearing loss. they need 
to know how and when to 
monitor, and how they can 
assess whether hearing loss 
is caused by CMV.
•	 Tracking longer-
term outcomes: our 
understanding of congenital 
CMV is still limited and there 
is an urgent need to monitor 
treatment and longer-term 
outcomes on a central uk 
database.
as the evidence in this report shows, the burden 
of CMV infection is high and the consequences far 
reaching. there is much that needs to be done if we 
are to achieve CMV action’s vision of fewer babies 
born with CMV and better support in place for those 
affected. but the good news is there’s plenty that 
can be done right now at little or no cost. 
ConCluSIon
Minimum standards of care for babies 
affected by CMV
local health systems should ensure that guidelines and 
pathways are in place for testing, diagnosis and management 
of CMV. these would include:
•	 Midwives, obstetricians and neonatologists should know the 
potential signs of congenital CMV in a newborn baby.
•	 a CMV test should take place as soon as hearing loss 
is confirmed and systems must be in place that make it 
possible to confirm or exclude CMV diagnosis within the first 
four weeks of life, so that treatment can be considered.
•	 the standard newborn hearing screen therefore needs to 
take place within a timeframe which allows diagnosis of 
congenital CMV within the first 4 weeks of life. 
•	 Following a diagnosis of CMV, families should have access 
to a paediatric infectious diseases specialist to discuss 
treatment.
•	 newborn Screening laboratories should retain Guthrie cards 
(dried blood spots) for as long as possible but at least the 
minimum period of 5 years. this is to enable the diagnosis 
of congenital CMV in children over 3 weeks of age who may 
present with problems during childhood, adolescence and as 
a young adult.
•	 the healthcare professional that is a family’s key point 
of contact must have knowledge of the evidence-based 
guidelines for managing CMV
Minimum standards of care for pregnant 
women
GPs should: 
•	 advise women trying to conceive on how to reduce the risk 
of CMV infection in the same way as they recommend folic 
acid before conception.
•	 advise pregnant women on how to reduce the risk of CMV 
infection in the same way they give advice on reducing the 
risk of food and animal-borne infections. 
Midwives should: 
•	 alert all the women booking with them to the dangers of 
CMV infection: how it spreads and how to reduce the risks, 
in the same way as they already advise about food and 
animal-borne infections.
•	 Support women with specific concerns about CMV enabling 
them to access support locally. 
Radiographers, sonographers and obstetricians should:
•	 be alert to indicators that suggest a higher risk of CMV, such 
as fetal anomalies, and take appropriate action.
Caroline Star 
CMV action Chair
there are also steps that 
can be taken at a national 
level. Public Health england 
should recognise CMV as a 
serious public health issue and 
support work on public and 
professional education, in the 
same way that the Centers for 
disease Control and Prevention 
(CdC) does in the uS. 
Research from other countries 
shows that implementation of 
guidelines can be hampered 
by lack of detailed knowledge 
of CMV. this is why alongside 
this report CMV action is 
launching training for midwives 
and will invest in training for 
doctors and other professionals 
in future. bodies responsible 
for professional training should 
also do more to ensure that 
doctors and midwives are 
confident in their knowledge of 
CMV prevention, transmission 
and management.
the national Institute for 
Health Research should 
support research into the 
prevention, detection and 
optimal management of 
congenital CMV.
We would also like to see an 
increase in research to develop 
an effective CMV vaccine. 
We recognise that our vision 
cannot be realised overnight, 
that it will take time and 
collaborative working to 
deliver. but it can and must be 
achieved if we are to reduce 
the unacceptable burden on 
the hundreds of young lives 
blighted each year through 
congenital CMV infection. 
let’s start that process now.
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